Envista Holdings, the parent company of KaVo Kerr, Nobel Biocare, and Ormco, has filed for an initial public offering (IPO). It hopes to raise more than $600 million, according to documents filed with the U.S. Securities and Exchange Commission.
Envista is a spin-off of Danaher, which first announced the plan to take the company public in July 2018. Envista plans to sell almost 27 million shares at $21 to $24 apiece ($602.3 million is the midpoint of that range). The stock will be traded on the New York Stock Exchange under the symbol NVST.
